A major milestone for Walloon biotech! EsoBiotec perfectly illustrates how our local #ecosystem can foster world-class #innovations. Behind every success, there are visionary entrepreneurs and committed investors. We are proud to have supported this journey and to contribute to the development of #biotech in our region. Congratulations to Jean-Pierre Latere Dwan'Isa and the entire team! Thanks to all the historical investors for their continued support : Thuja Capital, UCB Ventures, Invivo Partners, Wallonie Entreprendre and Sambrinvest.
We are proud to share that AstraZeneca is acquiring EsoBiotec! As an early-stage company pioneering in vivo cell therapies, we are advancing a platform with the potential to transform treatment delivery. Today, we announced a definitive agreement to join AstraZeneca. Our ENaBL platform is designed to eliminate traditional cell therapies' complex, time-consuming manufacturing process—replacing it with a simple IV injection that can be administered in minutes rather than weeks. CAR-T and other autologous therapies have revolutionized cancer treatment, but their high costs, logistical challenges, and long production timelines limit patient access. EsoBiotec’s in vivo approach has the potential to streamline treatment delivery, reduce barriers, and bring cell therapy to more patients faster. The acquisition deal includes an upfront payment of $425M, with up to $575M in milestone-based payouts. EsoBiotec will operate as a wholly owned subsidiary of AstraZeneca, further advancing in vivo cell therapy innovation. This marks a significant step toward making next-generation cell therapies more scalable and accessible. Read the full announcement here: https://lnkd.in/eNt6Wxtf #biotech #celltherapy #invivotherapy #astrazeneca #regenerativemedicine